Rheumatology Network's Top 5: October 1, 2022

Published on: 

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 1, 2022.

Upcoming Trial to Evaluate Safety, Efficacy of Guselkumab for Treatment of Axial PsA

Terence Rooney, MD, discusses the ongoing STAR study in depth and the potential of guselkumab to improve axial psoriatic arthritis.

Kim Bennell, PhD: Benefits of an Online Yoga Program for Patients with Knee Osteoarthritis

Kim Bennell, PhD, discusses her study “Effectiveness of an Unsupervised Online Yoga Program on Pain and Function in People With Knee Osteoarthritis: A Randomized Clinical Trial.”

Pirfenidone Slows Decline of Forced Vital Capacity in RA-Associated Interstitial Lung Disease

Although results are promising, findings should be interpreted with caution, as the study was underpowered and terminated early due to the COVID-19 pandemic.

Mycophenolic Acid Treatment Not Associated with More Severe COVID-19 Infection

Throughout the pandemic, rheumatologists have been concerned that their patients may be at risk of developing more severe forms of the COVID-19 disease as a result of their rheumatic disease or treatment.

Non-Pharmacological Therapies may Provide Alternative Treatment Options in Fibromyalgia

The 3-stage Delphi exercise used the expertise of medical and health care professionals with experience in treating patients with fibromyalgia. Treatment recommendations included exercise, education, cognitive behavioral therapy, mindfulness, and mind-body exercises.